This is the authors' abstract. We don't add key points for this paper.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer frequently associated with poor clinical outcomes. TNBC commonly exhibits a hypoxic tumor microenvironment that limits oxidative damage induced by reactive oxygen species (ROS), thereby reducing the effectiveness of dynamic therapy (DT). To address this challenge, the nanoradiosensitizer AIBN@F127 was developed to enable radiation-triggered free radical generation capable of inducing immunogenic cell death (ICD) for the radioimmunotherapy of TNBC. Upon X-ray irradiation, AIBN@F127 generates alkyl free radicals under both normoxic and hypoxic conditions, resulting in DNA damage, enhanced apoptosis, and improved anticancer efficacy. Our approach of radiotherapy with AIBN@F127 effectively amplifies ICD and promotes immune cell infiltration into tumors, potentially improving the outcomes of immunotherapy. Moreover, the combination of AIBN@F127-mediated irradiation with a programmed death ligand-1 inhibitor demonstrates promise in eliciting robust antitumor immune responses. Overall, this study presents an effective all-in-one strategy employing a radiation-triggered alkyl free radical generator to overcome key limitations in the treatment of hypoxic solid tumors.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: